| Document |
Document Title |
|
WO/2012/025638A1 |
The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.
|
|
WO/2012/019998A1 |
The invention relates to different methods for producing N'-(4-{[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl] oxy} -2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide.
|
|
WO/2012/013728A1 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a...
|
|
WO/2012/004714A2 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...
|
|
WO/2012/006104A2 |
The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus, and thus are useful in the treatment of tuberculosis infection and associated conditions. Th...
|
|
WO/2011/162514A2 |
The present invention provides a novel method for preparing [1,2,3]-oxathiazolidine-2,2-dioxide or [1,2,5]-thiadiazolidine-1,1-dioxide derivatives. According to the manufacturing method of the present invention, it is possible to conveni...
|
|
WO/2011/156655A2 |
Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for u...
|
|
WO/2011/152471A2 |
Provided is a rechargeable battery with a higher degree of safety. Specifically provided is a rechargeable battery constituted so as to prevent overcharging. The rechargeable battery is a battery which uses a positive electrode material ...
|
|
WO/2011/132712A1 |
Provided is a novel compound that is useful as a medical drug in that said compound displays strong antimicrobial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant strains thereof, on the basis of ...
|
|
WO/2011/082941A1 |
The present invention relates to benzyl-substituted thiadiazolyl oxyphenyl amidinium salts of the general formula (I), to a method for the production thereof, to the use of the amidinium salts according to the invention for combatting un...
|
|
WO/2011/083265A1 |
The invention relates to compounds of formula (I): where R1 and R2, identical or different, each represent a hydrogen or halogen atom or a cyano, hydroxyl, thio, nitro, alkyl, alkoxy, alkylthio, carboxy, alkoxycarbonyl, acyloxy, amino, a...
|
|
WO/2011/082400A2 |
Disclosed are an assay to identify modulators of the PD-1 :PD-L pathway and PD-1 :PD-L pathway modulators, e.g., compounds and pharmaceutical compositions thereof. Methods for treating diseases influenced by modulation of the PD-1 :PD-L ...
|
|
WO/2011/070177A2 |
Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFRα receptor molecules, ...
|
|
WO/2011/069647A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: wherein:. L represents a direct bond or a -S(O)2- group, • n is an integer having a value from 0 to 2, • R1 represe...
|
|
WO/2011/071095A1 |
Disclosed is a compound which is useful as a GK activator. Studies have been made on compounds which have a GK activating action and are therefore promising as active ingredients of pharmaceutical compositions for the treatment of diabet...
|
|
WO/2011/069045A2 |
The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.
|
|
WO/2011/061110A1 |
The invention relates to alkylsulfide derivatives compounds of formula I as hererunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular a...
|
|
WO/2011/059042A1 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...
|
|
WO/2011/054947A1 |
The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: R1 is C1-3alkyl or C1fluoroalkyl-CH2; R2 is hydrogen, C1-4alkyl, C1fluoroalkyl-CH2-, C3-6cycloalkyl, C3-6cycloalkyl-methyl-, optional...
|
|
WO/2011/052727A1 |
Disclosed is a compound which has a light absorption end wavelength that is a long wavelength. Specifically disclosed is a compound which contains a structural unit represented by formula (1). (In the formula, Ar1 and Ar2 each represents...
|
|
WO/2011/049531A1 |
The invention provides organic compounds of formula I, wherein each A is an independently selected conjugated electron withdrawing aromatic or heteroaromatic group; each D is an independently selected ethenylene group, ethynylene group o...
|
|
WO/2011/046954A1 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
WO/2011/042523A1 |
The invention relates to a thiadiazole of formula (I).
|
|
WO/2011/042525A1 |
The invention relates to a rubber composition for producing tyres, based on at least one dienic elastomer, at least one reinforcing load, and a vulcanisation system, characterised in that said vulcanisation system comprises at least one ...
|
|
WO/2011/039403A1 |
The present invention relates to the use of a broad family of substituted 5-imino-1,2,4-thiadiazoles as potential novel drugs for treating diseases in which PDE7 inhibition is relevant, especially inflammatory, autoimmune and neurodegene...
|
|
WO/2011/035900A1 |
The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are usef...
|
|
WO/2011/027888A1 |
Disclosed are a diamide-phenyl derivative which inhibits soluble epoxy hydrolase (sEH), and a pharmaceutically acceptable salt of the diamide-phenyl derivative. Specifically disclosed are a compound represented by formula (I), and a phar...
|
|
WO/2011/023864A1 |
The invention relates to compounds, in particular MMP inhibitors. The compounds of the invention have formula (1). The invention can be used in particular in the pharmaceutical field. The present invention also relates to labeled compoun...
|
|
WO/2011/021696A1 |
Provided are a palladium ion adsorbent for solid-liquid adsorption which has both the extraction performance and selectivity of a palladium extractant for liquid-liquid extraction used in conventional solvent extraction methods and which...
|
|
WO/2011/004162A2 |
According to the invention there is provided a compound of formula (I), wherein, X, W, A1 to A5 and D have meanings given in the description, which compounds are useful in the treatment of cancer.
|
|
WO/2010/148488A1 |
The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including...
|
|
WO/2010/148963A1 |
Compounds represented by formula (I) or pharmaceutically acceptable salts or hydrates thereof, and use of the compounds in the manufacture of medicaments against virus, preferably hepatitis virus, such as hepatitis C virus and hepatitis ...
|
|
WO/2010/148650A1 |
5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.
|
|
WO/2010/148649A1 |
5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.
|
|
WO/2010/146083A1 |
This invention is directed to compounds of the formula (I) and salts therefore that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes...
|
|
WO/2010/137350A1 |
Disclosed is a compound which enhances the activity of neurotrophic factors and exerts a protective action on nerve cells. Specifically disclosed is a compound represented by formula (Ia) or (Ib), a pharmaceutically acceptable salt there...
|
|
WO/2010/130944A1 |
The invention relates to compounds of the general formula (I) where: R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, or NR8R9 group; m, n, o and p independently are a number from 0 to 3; ...
|
|
WO/2010/130934A2 |
The invention relates to 2-cycloamino-5-(pyridin-4-yl)imidazo[2,1-b][1,3,4]thiadiazol
e derivatives of the general formula (I) where: R5 is a hydrogen atom or a C1-3 alkyl, -NR7R8, or C1-3 alkyloxy group; R6 is an optionally substituted ...
|
|
WO/2010/127928A1 |
The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, n...
|
|
WO/2010/125991A1 |
Disclosed is a method for controlling fish parasites, which comprises continuously administering a folic acid synthesis inhibitor and/or a folic acid activation inhibitor to a fish at a dose of 1 to 50 mg/kg fish body weight per day for ...
|
|
WO/2010/117662A1 |
The invention is directed to Compounds of Formula (I): as well as methods of making and using the compounds.
|
|
WO/2010/114107A1 |
An actinic ray-sensitive or radiation-sensitive resin composition includes: (A) a resin capable of increasing a solubility of the resin (A) in an alkali developer by an action of an acid; and (B) a compound capable of generating an acid ...
|
|
WO/2010/111574A1 |
Cannabinoid receptor ligands of formula (I) wherein Ring A and R1 are as defined in the specification. Compositions including such compounds, and methods of treating conditions and disorders using such compounds and compositions are also...
|
|
WO/2010/111573A1 |
Disclosed herein are cannabinoid receptor ligands of formula (I) wherein Ring A and R1 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds an...
|
|
WO/2010/108903A1 |
The present invention relates to compounds of formula (I), wherein R1a to R1e, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically 5 ...
|
|
WO/2010/106249A1 |
The invention relates to compounds of formula (I), where: R1 and R2 are identical or different, each being a hydrogen or halogen atom, or an alkyl, alkoxy, alkylthio, acyl, alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, cyano, nitro, am...
|
|
WO/2010/099786A1 |
The invention relates to chiral disulfonimides having the general formula I to III, wherein at least one of the groups A and B in the compound of formula I, C and D of the compound in formula II, and E and F of the compound in formula II...
|
|
WO/2010/086551A1 |
The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic a...
|
|
WO/2010/086613A1 |
According to the invention there is provided a compound of formula (I), wherein, X, T, Y1 E, M, A1 to A5 and D1 to D5 have meanings given in the description, which compounds are useful in the treatment of cancer.
|
|
WO/2010/083442A1 |
Disclosed are compounds of Formula (1), in which A1, Z1, Z1A, Z2, Z2A, L1 and Z3 are as defined in the claims, which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and their use in treating d...
|
